MIRA INFORM
REPORT
|
Report Date : |
11.07.2011 |
IDENTIFICATION DETAILS
|
Name : |
RODAN INTERNATIONAL CO LTD. |
|
|
|
|
Registered Office : |
3/F., No. 158, Sec.2 Min Chuan Road, Chungxi District, Tainan
City |
|
|
|
|
Country : |
Taiwan |
|
|
|
|
Date of Incorporation : |
03.08.1988 |
|
|
|
|
Com. Reg. No.: |
23030104 |
|
|
|
|
Legal Form : |
Joint Stock Company |
|
|
|
|
Line of Business : |
Import and sales
of bulk pharmaceutical chemicals, etc |
RATING & COMMENTS
|
MIRA’s Rating : |
B |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
Maximum Credit Limit : |
USD 40,000 |
|
|
|
|
Status : |
Small Company |
|
|
|
|
Payment
Behaviour : |
No Complaints |
|
|
|
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31st, 2011
|
Country Name |
Previous Rating (31.12.2010) |
Current Rating (31.03.2011) |
|
Taiwan |
a2 |
a2 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
Contact
Points
Notes: Subject’s exact name and address are as
above.
Credit
Summary
|
Credit Rating: |
|
|
Credit Opinion: |
Company
Identification Details
|
Registered Name: |
Rodan
International Co Ltd. |
|
Registered
Address: |
3/F., No. 158, Sec.2
Min Chuan Road, Chungxi District, Tainan City, Taiwan |
|
Date of
Foundation: |
|
|
Registration
Number: |
23030104 |
|
Registry: |
MOEA Central
Office |
|
Registered
Capital: |
(As of 2011.07, 1
NTD = 0.0348 USD) |
|
Paid-up Capital: |
NTD 5,000,000
(USD 174,000) |
|
Legal
Representatives: |
Zhengzhi Zhang |
|
Legal Form: |
|
|
Principal
Activities: |
|
|
Staff: |
|
|
Listed at Stock Exchange: |
|
|
Date of Last Annual Return: |
Notes: Subject declined to disclose its staff information;
from other source we can not obtain the relevant information, either.
History
Subject was incorporated on
Shareholders
|
Name |
Subscription
Shares |
|
Zhengzhi Zhang |
100 |
| Hehui Suzhang |
500 |
|
Wenxiu Luo |
200 |
|
Changmei Luo |
250 |
The information above is that of subject’s major
shareholders.
Subsidiaries &
Branches
Related Company:
|
Name: |
Chong Dah
Pharmaceutical Co., Ltd. |
|
Tel: |
+886-6-221-4725 |
|
Fax: |
+886-6-220-1677 |
|
E-mail: |
Personnel
Information
Core Management
|
1 |
|
|
Name |
Zhengzhi Zhang |
|
Position |
Board Chairman |
|
2 |
|
|
Name |
Hehui Suzhang |
|
Position |
Director |
|
3 |
|
|
Name |
Wenxiu Luo |
|
Position |
Director |
|
4 |
|
|
Name |
Changmei Luo |
|
Position |
Supervisor |
Operation
Information
Offices & Factories
|
|
Headquarters
|
|
Add |
3/F., No. 158, Sec.2
Min Chuan Road, Chungxi District, Tainan City, Taiwan |
Production Information
l
Subject
is a distributor of bulk pharmaceutical chemicals without any production
activities
Purchase Information
l
The
registered activities of subject:
|
Business Code |
Details |
|
F102170 |
Wholesales of food and groceries |
|
F103010 |
Wholesales of feed |
|
F107020 |
|
|
F107070 |
Wholesales of medicines used on animals |
|
F107200 |
Wholesales of chemical materials |
|
F107990 |
Wholesales of other chemicals |
|
F108021 |
Wholesales of Western medicine |
|
F108031 |
|
|
F108040 |
Wholesales of cosmetics |
|
F202010 |
Retails of feed |
|
F203010 |
Retails of food, groceries,
and beverage |
|
F207020 |
|
|
F207070 |
Retails of medicines used on animals |
|
F207200 |
Retails of chemical materials |
|
F207990 |
Retails of other chemicals |
|
F208021 |
Retails of Western medicine |
|
F208031 |
|
|
F208040 |
Retails of cosmetics |
|
F208050 |
l
Subject
purchases bulk pharmaceutical chemicals mainly broad such as India, Germany and
Thailand, etc
l
It is
introduced that subject usually has inventories to satisfy the domestic
customers.
l
Subject
has stable suppliers as follows:
Major brands and suppliers:
|
Region |
Brand |
|
India |
Ranbaxy |
|
Germany |
Giulini |
|
Thailand, India |
Lupin |
l
The
subject is mainly engaged in sales of bulk pharmaceutical chemicals, etc.
l
Subject’s
products are mainly sold in domestic market of Taiwan and it is introduced that
subject’s customers are mainly pharmaceutical factories, etc
Settlements
Purchase
Domestic
Purchase
Subject has little domestic purchase.
|
Payment
Terms |
Proportion |
|
|
Bulk
pharmaceutical chemicals |
CBD,
etc |
100% |
Sales
Domestic
Markets
|
Sales
Terms |
Proportion |
|
|
Bulk
pharmaceutical chemicals |
COD,
CBD, etc |
100% |
Export
Financial
Information
Subject has no
obligations to disclose its financial statements to the third party according
to the relevant policy in Taiwan and the only source from which we can obtain
the information is the subject itself.
Subject’s relevant
staff Ms. Sun declined to disclose its financials citing the grounds of company’s
confidentiality; from other source we can not obtain the relevant information, either.
Bankers
Subject declined to
disclose its bank details; from other source we can not obtain the relevant
information, either.
Public
Record
Mortgage
No chattel mortgage
record of subject has been found within the recent 3 months.
Lawsuit
Up to date of reporting, no existing or
latent litigation of the subject has been found.
Interview
Details
|
Name |
Ms. Sun |
|
Department |
Sales department |
|
E-mail |
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.44.33 |
|
UK Pound |
1 |
Rs.70.74 |
|
Euro |
1 |
Rs.63.65 |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
---- |
NB |
New Business |
---- |
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this
report. The assessed factors and their relative weights (as indicated through
%) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.